Exploring 3 High Growth Tech Stocks in the United States
In This Article:
Over the last 7 days, the United States market has risen by 1.6%, and in the past year, it has climbed an impressive 32%, with earnings forecasted to grow by 15% annually. In light of these robust market conditions, identifying high growth tech stocks requires a focus on companies that demonstrate strong innovation potential and scalability to align with this upward trajectory.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 23.83% | 23.74% | ★★★★★★ |
| Ardelyx | 25.24% | 69.64% | ★★★★★★ |
| Sarepta Therapeutics | 24.00% | 42.49% | ★★★★★★ |
| Clene | 78.50% | 60.16% | ★★★★★★ |
| TG Therapeutics | 34.66% | 56.98% | ★★★★★★ |
| Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.44% | 70.66% | ★★★★★★ |
| Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Incyte
Simply Wall St Growth Rating: ★★★★★☆
Overview: Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for hematology/oncology as well as inflammation and autoimmunity, with a market cap of approximately $14.41 billion.
Operations: Incyte generates revenue primarily from its biotechnology segment, amounting to $4.08 billion. The company is involved in the discovery, development, and commercialization of therapeutics targeting hematology/oncology and inflammation/autoimmunity markets both domestically and internationally.
Incyte, navigating through a challenging landscape marked by a notable 46.5% anticipated annual earnings growth, contrasts sharply with its current revenue trajectory which lags behind at 9% annually. This juxtaposition highlights the firm's strategic emphasis on innovation despite market pressures, underscored by its substantial R&D commitment—evident from recent adjustments to clinical trials and product pipelines that could reshape future operations. Moreover, recent corporate maneuvers including revised upward revenue forecasts suggest adaptive strategies to maintain competitiveness in a volatile sector.
-
Click to explore a detailed breakdown of our findings in Incyte's health report.
-
Examine Incyte's past performance report to understand how it has performed in the past.
Iris Energy
Simply Wall St Growth Rating: ★★★★★☆
Overview: Iris Energy Limited owns and operates bitcoin mining data centers, with a market cap of $1.81 billion.
Operations: Iris Energy focuses on bitcoin mining through its data centers. The company generates revenue primarily from the production and sale of mined bitcoins, leveraging its infrastructure to optimize operational efficiency.